Evidence map›Paper›PMID 39680179›Full record

ArticleJournal of neurology2024

Serum neurofilament light chain as a diagnostic and prognostic biomarker in multiple system atrophy: a prospective cohort study.

Min Liu, Yanning Cai, Jing Pan, Ting Wang, Yuan Li, Qian Yu, Wei Mao, Piu Chan

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min LiuDepartment of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China.
Yanning CaiDepartment of Neurobiology, Clinical Center for Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory for Parkinson's Disease, Xuanwu Hospital of Capital Medical University, Beijing, China.
Jing PanDepartment of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China.
Ting WangDepartment of Neurobiology, Clinical Center for Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing Key Laboratory for Parkinson's Disease, Xuanwu Hospital of Capital Medical University, Beijing, China.
Yuan LiDepartment of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China.
Qian YuSchool of Health Professions, Stony Brook University, Stony Brook, New York, USA.
Wei MaoDepartment of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China. wei.mao@ccmu.edu.cn.ORCID http://orcid.org/0000-0002-7690-9013
Piu ChanDepartment of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital Capital Medical University, Beijing Institute of Geriatrics, 45 Changchun Street, Xicheng District, Beijing, 100053, China. pbchan@hotmail.com.

Funding

Beijing Traditional Chinese Medicine Technology Development Fund Project BJZYQN-2023-10Key Realm R&D Program of Guangdong Province 2018B030337001the National Key R&D Program of China 2017YFC0840105the National Key R&D Program of China 2017YFC1310200the National Key R&D Program of China 2018YFC1312001the National Key R&D Program of China 2021YFC2501200the National Key R&D Program of China 2021YFC2501205
6 · The paper itself

Abstract

backgroundNeurofilament light chain (NFL) in blood has been identified as a valuable biomarker in multiple system atrophy (MSA), but data regarding its utility in the early diagnosis and prognosis of MSA remain limited.

objectiveTo investigate serum NFL's diagnostic and prognostic value in patients with MSA in a prospective clinical cohort.

methodsTwo hundred twenty-eight participants were enrolled, including ninety-eight with MSA, seventeen with uncertain MSA at inclusion, fifty-nine with Parkinson's disease (PD), and fifty-four healthy controls (HCs). Patients with MSA and uncertain diagnoses were followed up. Serum NFL levels were measured with electrochemiluminescence immunoassay at baseline.

resultsPatients with MSA and uncertain diagnoses underwent repeated clinical assessments with a median follow-up period of 1.43 years. The final diagnoses included 102 MSA, 62 PD, and 54 HCs. Serum NFL levels were significantly higher in MSA and PD than in HCs. Serum NFL levels, with cutoff values of 223.5 and 218.0 pg/mL, could discriminate between patients with MSA and PD (AUC = 0.930) in the early disease stages, and between MSA-parkinsonism subtypes and PD (AUC = 0.878). Higher serum NFL levels were independently associated with a shorter median time to poor prognosis and death. In addition, reduced levodopa responsiveness was correlated with poor outcomes, and orthostatic hypotension (OH) was linked to a higher risk of death.

conclusionSerum NFL levels can not only differentiate between MSA, MSA-P, and PD in the early stages of the disease but also serve as a reliable independent predictor of poor prognosis and survival time in MSA.

Indexed as

BiomarkersMultiple System AtrophyNeurofilament ProteinsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedParkinson DiseasePrognosisProspective StudiesBiomarkersneurofilament protein LNeurofilament ProteinsDiagnosis and prognosisMultiple system atrophyNeurofilament light chain

Identifiers

PMID39680179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.